Equities Analysts Offer Predictions for CRSP FY2027 Earnings

Key Points

• HC Wainwright projects FY2027 EPS of ($5.00) for CRISPR Therapeutics, slightly below the consensus estimate of ($4.93), indicating continued expected losses.
• The company missed Q1 expectations, reporting EPS of ($1.28) vs. consensus ($1.22) and revenue of $1.46M versus $6.06M expected, though revenue was up 68.6% year‑over‑year.
• Analysts have a consensus "Moderate Buy" rating with a price target of $64.53; shares trade around $52.38 and insiders sold about 51,828 shares (~$2.58M) over the past three months.

CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) - Research analysts at HC Wainwright issued their FY2027 earnings per share estimates for shares of CRISPR Therapeutics in a note issued to investors on Tuesday, May 5th. HC Wainwright analyst M. Kapoor expects that the company will earn ($5.00) per share for the year. The consensus estimate for CRISPR Therapeutics' current full-year earnings is ($4.93) per share.

CRSP has been the subject of several other reports. Truist Financial upgraded CRISPR Therapeutics to a "strong-buy" rating in a report on Wednesday, March 25th. Piper Sandler reiterated an "overweight" rating and issued a $110.00 target price (up from $105.00) on shares of CRISPR Therapeutics in a report on Tuesday, March 17th. Chardan Capital upped their target price on CRISPR Therapeutics from $74.00 to $76.00 and gave the stock a "buy" rating in a report on Saturday, February 14th. Citigroup reiterated a "buy" rating on shares of CRISPR Therapeutics in a report on Monday, February 16th. Finally, Evercore reiterated an "outperform" rating and issued a $74.00 target price on shares of CRISPR Therapeutics in a report on Friday, February 13th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, six have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, CRISPR Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $64.53.

CRISPR Therapeutics Trading Down 2.2%

Shares of CRSP stock opened at $52.38 on Wednesday. CRISPR Therapeutics has a twelve month low of $33.03 and a twelve month high of $78.48. The stock has a market capitalization of $5.05 billion, a price-to-earnings ratio of -8.42 and a beta of 1.74. The stock has a fifty day simple moving average of $52.41 and a two-hundred day simple moving average of $54.60.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last issued its earnings results on Tuesday, May 5th. The company reported ($1.28) earnings per share for the quarter, missing the consensus estimate of ($1.22) by ($0.06). CRISPR Therapeutics had a negative return on equity of 25.53% and a negative net margin of 13,856.54%.The firm had revenue of $1.46 million during the quarter, compared to analysts' expectations of $6.06 million. During the same quarter in the prior year, the company posted ($1.58) earnings per share. CRISPR Therapeutics's quarterly revenue was up 68.6% compared to the same quarter last year.

Insider Activity

In other news, insider Naimish Patel sold 3,150 shares of the stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $48.26, for a total value of $152,019.00. Following the transaction, the insider directly owned 13,143 shares of the company's stock, valued at approximately $634,281.18. This represents a 19.33% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, General Counsel James R. Kasinger sold 3,450 shares of the stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $48.26, for a total value of $166,497.00. Following the completion of the transaction, the general counsel directly owned 91,240 shares in the company, valued at $4,403,242.40. This represents a 3.64% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 51,828 shares of company stock valued at $2,578,097. Company insiders own 4.10% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of CRSP. Mcguire Capital Advisors Inc. acquired a new position in shares of CRISPR Therapeutics in the fourth quarter valued at about $25,000. Ramirez Asset Management Inc. acquired a new position in shares of CRISPR Therapeutics in the fourth quarter valued at about $26,000. Rothschild Investment LLC increased its holdings in shares of CRISPR Therapeutics by 836.7% in the fourth quarter. Rothschild Investment LLC now owns 562 shares of the company's stock valued at $29,000 after purchasing an additional 502 shares during the period. Thurston Springer Miller Herd & Titak Inc. grew its holdings in CRISPR Therapeutics by 196.9% during the fourth quarter. Thurston Springer Miller Herd & Titak Inc. now owns 576 shares of the company's stock worth $30,000 after acquiring an additional 382 shares during the period. Finally, Optiver Holding B.V. grew its holdings in CRISPR Therapeutics by 71.4% during the third quarter. Optiver Holding B.V. now owns 504 shares of the company's stock worth $33,000 after acquiring an additional 210 shares during the period. 69.20% of the stock is owned by institutional investors and hedge funds.

About CRISPR Therapeutics

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.